PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16647690-5	2006	There was a significant decrease in binding of the specific GABABR antagonist, [3H]CGP-54626A at postnatal day (PN)7 and PN14 in SSADH(-/-) when compared to wild type control animals (SSADH(+/+)), particularly in hippocampus.	gababr	60-66	aldehyde dehydrogenase 5 family member A1	Homo sapiens	129-139	
16647690-5	2006	There was a significant decrease in binding of the specific GABABR antagonist, [3H]CGP-54626A at postnatal day (PN)7 and PN14 in SSADH(-/-) when compared to wild type control animals (SSADH(+/+)), particularly in hippocampus.	gababr	60-66	aldehyde dehydrogenase 5 family member A1	Homo sapiens	129-134	
16647690-6	2006	GABABR-mediated synaptic potentials were decreased in SSADH(-/-).	gababr	0-6	aldehyde dehydrogenase 5 family member A1	Homo sapiens	54-64	
16647690-9	2006	These data suggest that the elevated levels of GABA and GHB that occur in SSADH(-/-) lead to a use-dependent decrease in GABABR-mediated function and raise the possibility that this GHB- and GABA-induced perturbation of GABABR could play a role in the pathogenesis of the seizures and mental retardation observed in SSADH deficiency.	gababr	121-127	aldehyde dehydrogenase 5 family member A1	Homo sapiens	74-84	
16647690-9	2006	These data suggest that the elevated levels of GABA and GHB that occur in SSADH(-/-) lead to a use-dependent decrease in GABABR-mediated function and raise the possibility that this GHB- and GABA-induced perturbation of GABABR could play a role in the pathogenesis of the seizures and mental retardation observed in SSADH deficiency.	gababr	220-226	aldehyde dehydrogenase 5 family member A1	Homo sapiens	74-84